NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Forecast, Price & News

$2.85

-0.02 (-0.70%)

(As of 09/28/2023 ET)

Compare

Today's Range: $2.83
▼
$2.92
50-Day Range: $2.68
▼
$3.08
52-Week Range: $0.89
▼
$3.29

Volume: 67,276 shs
Average Volume: 400,359 shs
Market Capitalization: $121.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.50

Talaris Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 163.2% Upside
$7.50 Price Target
Short Interest: Healthy
2.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

668th out of 969 stocks

Biological Products, Except Diagnostic Industry

106th out of 161 stocks

3.0

Analyst's Opinion

Consensus Rating
Talaris Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.50, Talaris Therapeutics has a forecasted upside of 163.2% from its current price of $2.85.
Amount of Analyst Coverage
Talaris Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.79% of the float of Talaris Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Talaris Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Talaris Therapeutics has recently increased by 24.10%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Talaris Therapeutics does not currently pay a dividend.
Dividend Growth
Talaris Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TALS.

1.9

News and Social Media Coverage

News Sentiment
Talaris Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Talaris Therapeutics this week, compared to 1 article on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Talaris Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.50% of the stock of Talaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.61% of the stock of Talaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Talaris Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Talaris Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Talaris Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Talaris Therapeutics (NASDAQ:TALS) Stock

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

TALS Price History

30 days | 90 days | 365 days | Advanced Chart

TALS Stock News Headlines

September 12, 2023 | finance.yahoo.com

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

August 15, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOT

September 28, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

August 14, 2023 | finance.yahoo.com

ImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Business

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF

July 28, 2023 | benzinga.com

Moore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firm

July 27, 2023 | markets.businessinsider.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)

July 18, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMS

September 28, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

July 18, 2023 | msn.com

Talaris Therapeutics: Cashing Out Ahead Of Tourmaline Merger

July 6, 2023 | msn.com

Talaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75

June 27, 2023 | markets.businessinsider.com

IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETI

June 26, 2023 | businesswire.com

TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS

June 23, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Talaris Therapeutics, Inc. Merger

June 23, 2023 | bizjournals.com

Talaris Therapeutics announces merger after layoffs

June 22, 2023 | bizjournals.com

NY biotech to go public by merging with Boston firm that laid off 95% of staff

June 22, 2023 | msn.com

Talaris jumps 29% on merger with Tourmaline Bio in all-stock deal

June 22, 2023 | markets.businessinsider.com

IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR

June 22, 2023 | finanznachrichten.de

Talaris Therapeutics, Inc.: Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

June 22, 2023 | msn.com

Talaris Soars on All Stock Deal with Tourmaline Bio

June 22, 2023 | stockhouse.com

TALS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Talaris Therapeutics, Inc. Is Fair to Shareholders

June 22, 2023 | benzinga.com

Why Talaris Therapeutics Stock Is Shooting Higher Today

June 22, 2023 | seekingalpha.com

Talaris to merge with Tourmaline Bio in all-stock deal

June 22, 2023 | markets.businessinsider.com

Tourmaline, Talaris Announce All-stock Merger

June 22, 2023 | finance.yahoo.com

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

June 15, 2023 | benzinga.com

Talaris Therapeutics Board Member Awarded $50K Worth of Stock Options

June 15, 2023 | benzinga.com

Talaris Therapeutics Director Awarded $50K Worth of Stock Options

See More Headlines

Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TALS Company Calendar

Last Earnings: 8/14/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TALS
CUSIP: N/A
CIK: 1827506
Web: talaristx.com
Phone: 502-398-9250
Fax: N/A
Employees: 84
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.50
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +163.2%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-73,890,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -39.93%
Return on Assets: -37.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.41
Quick Ratio: 15.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.33 per share
Price / Book: 0.66

Miscellaneous

Outstanding Shares: 42,760,000
Free Float: 35,708,000
Market Cap: $121.87 million
Optionable: Not Optionable
Beta: 2.26

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Ms. Mary Kay Fenton (Age 59)
Interim CEO, Pres, CFO & Treasurer
Comp: $598.98k

Dr. Suzanne T. Ildstad M.D. (Age 70)
Founder, Member of Scientific Advisory Board, Sr. Scientific Advisor & Director
Comp: $318.3k

Ms. Suzanne Tollerud
VP of Corp. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TALS Stock - Frequently Asked Questions

Should I buy or sell Talaris Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Talaris Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TALS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TALS, but not buy additional shares or sell existing shares.
View TALS analyst ratings or view top-rated stocks.
What is Talaris Therapeutics' stock price forecast for 2023?: 2 brokerages have issued 1 year price targets for Talaris Therapeutics' shares. Their TALS share price forecasts range from $3.00 to $12.00. On average, they expect the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 163.2% from the stock's current price.
View analysts price targets for TALS or view top-rated stocks among Wall Street analysts.
How have TALS shares performed in 2023?: Talaris Therapeutics' stock was trading at $1.02 on January 1st, 2023. Since then, TALS shares have increased by 179.4% and is now trading at $2.85.
View the best growth stocks for 2023 here.
Are investors shorting Talaris Therapeutics?: Talaris Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 593,800 shares, an increase of 24.1% from the August 31st total of 478,500 shares. Based on an average daily trading volume, of 308,800 shares, the days-to-cover ratio is currently 1.9 days. Currently, 2.8% of the company's stock are sold short.
View Talaris Therapeutics' Short Interest.
When is Talaris Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our TALS earnings forecast.
How were Talaris Therapeutics' earnings last quarter?: Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its earnings results on Monday, August, 14th. The company reported ($0.20) earnings per share for the quarter.

When did Talaris Therapeutics IPO?: (TALS) raised $150 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.
What is Talaris Therapeutics' stock symbol?: Talaris Therapeutics trades on the NASDAQ under the ticker symbol "TALS."
Who are Talaris Therapeutics' major shareholders?: Talaris Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (5.55%), BML Capital Management LLC (4.76%), Great Point Partners LLC (1.59%), JPMorgan Chase & Co. (1.08%), Renaissance Technologies LLC (1.05%) and Walleye Capital LLC (0.73%). Insiders that own company stock include Francois Nader, Longitude Capital Partners Iii, Sandip Agarwala, Scott Requadt and Suzanne Ildstad.
View institutional ownership trends.
How do I buy shares of Talaris Therapeutics?: Shares of TALS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Talaris Therapeutics' stock price today?: One share of TALS stock can currently be purchased for approximately $2.85.
How much money does Talaris Therapeutics make?: Talaris Therapeutics (NASDAQ:TALS) has a market capitalization of $121.87 million. The company earns $-73,890,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.
How can I contact Talaris Therapeutics?: The official website for the company is talaristx.com. The company can be reached via phone at 502-398-9250.

This page (NASDAQ:TALS) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial